Kenvue (KVUE) DIvidends Date & History

Key Takeaways

• Kenvue Inc. (KVUE) provides a trailing annual dividend yield of 4.71% and forward yield of 4.76%, paid quarterly at $0.2075 per share.
• Recent dividend increase to $0.2075 reflects modest growth since its 2023 spin-off from Johnson & Johnson.
• Payout ratio stands at 108.55%, exceeding earnings coverage but supported by $1.81 billion in levered free cash flow (FCF) trailing twelve months (ttm).
• Debt-to-equity ratio of 80.58% is moderate for the consumer health sector, aiding dividend stability.
• Yield exceeds consumer health peers, appealing to income-focused investors seeking higher payouts.
• Next ex-dividend date is May 13, 2026, with payment on May 27, 2026.

Dividend Overview

Kenvue Inc. (KVUE), the world's largest pure-play consumer health company, maintains a quarterly dividend policy with a forward annual payout of $0.83 per share. This delivers a forward yield of 4.76% based on recent trading levels around $17.43. The most recent declaration on April 29, 2026, raised the quarterly dividend to $0.2075 per share, payable May 27 to shareholders of record by May 13. Since its spin-off from Johnson & Johnson in May 2023, KVUE has positioned itself as a high-yield stock in the consumer health space, rather than a dividend growth aristocrat. Its profile suits income investors prioritizing current yield over rapid increases, backed by iconic brands like Tylenol, Neutrogena, and Listerine generating steady cash flows.

Dividend History and Growth

Launched as a public company in 2023, KVUE has paid consistent quarterly dividends without interruption. Early payouts hovered around $0.20 per share, progressing to $0.205 and now $0.2075—a modest 1.2% year-over-year growth in the latest adjustment. This reflects a conservative strategy focused on stability amid post-spin-off integration. Lacking a multi-decade growth streak, KVUE does not qualify as a dividend aristocrat but demonstrates reliability through four annual payments. Long-term, management emphasizes sustainable payouts tied to operational performance in self-care, skin health, and essential health segments.

Dividend Sustainability and Payout Ratio

KVUE's payout ratio of 108.55% indicates dividends exceed current earnings per share (EPS) of approximately $0.76 trailing twelve months. However, sustainability is bolstered by robust cash generation: operating cash flow (OCF) ttm at $2.2 billion and levered FCF at $1.81 billion comfortably covers the estimated $1.59 billion annual dividend obligation. With total debt of $8.67 billion against $1.06 billion in cash, the debt-to-equity ratio of 80.58% remains manageable for a staples-like business. Profit margins of 9.72% and operating margins of 17.83% support ongoing coverage, though earnings growth will be key to easing payout pressures.

Dividend Compared to Industry Peers

In the consumer health and personal products industry, KVUE's 4.7% yield significantly outpaces peers. Procter & Gamble (PG) offers around 2.5%, Colgate-Palmolive (CL) about 2.1%, and Kimberly-Clark (KMB) roughly 3.5-4%. Johnson & Johnson (JNJ), its former parent, yields near 3%. KVUE's higher payout reflects its pure consumer health focus and post-spin-off capital structure, providing a relative bargain for yield hunters, though with elevated payout scrutiny versus more conservative peers.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover high-yield consumer health plays like KVUE.

Is This Stock Attractive for Dividend Investors?

KVUE appeals to income investors chasing above-market yields in defensive consumer staples, where its 4.7% payout stands out amid economic uncertainty. The FCF-backed quarterly dividends suit those prioritizing reliable cash returns over aggressive growth, especially given stable demand for essential health products. Conservative investors may appreciate the brand moat and moderate leverage, though the payout ratio above 100% warrants monitoring earnings trajectory. Dividend growth seekers might find modest raises insufficient compared to aristocrats, but long-term holders could benefit from potential multiple expansion if profitability improves. Overall, it fits portfolios emphasizing current income in health care, balanced against sustainability risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations